| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 28% YoY growth in Q1 FY27. |
|---|---|
| Margins | Targeting 15%+ EBITDA margins as capacity utilization improves. |
| Demand visibility | Positive momentum in domestic and international specialty chemicals. |
| Management confidence | Bullish on prospects, especially international markets and new product ramps. |
Growth
Consolidated revenue grew 28% YoY; HPPC, TSC, and AHN segments each grew approximately 28% YoY; Exports up 21%.
Outlook
Management targets 15% top-line growth for FY27 and aims for 15%+ steady-state EBITDA margins through B2C rationalization.
Risks
EBITDA margins compressed to 11.6% from 12.5% due to raw material volatility, freight costs, and B2C segment losses.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 28% (= BEAT)
- Guided 12-13% EBITDA margin → delivered 11.6% (= PARTIAL)
- Guided Thailand plant operational Q2 → delivered operational (= BEAT)
Partly delivered
- Guided debt reduction/debt-free 18mo → delivered net debt Rs. 248 Cr (= PARTIAL)
Missed
- Guided B2C/Institutional breakeven FY27 → delivered losses (= MISS)
Investor Presentation filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹444.20
- Market cap
- ₹2,461 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 16.3×Sector 37.5×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech achieved highest-ever Q4 revenue and EBITDA in FY26, driven by 15% volume-led annual revenue growth. Focus is shifting toward high-margin pharma and oil & gas segments.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.
Rossari Biotech Q4 FY26 Results: Net Profit ₹46 Cr, Up 33.7% YoY
Rossari Biotech Ltd reported revenue from operations of ₹684.9 Cr (+18.2% YoY) and net profit of ₹46 Cr (+33.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹46 Cr · +33.7% YoY